Abatacept for SLE Arthritis (IM101-330)

Efficacy of Abatacept in Inflammatory Polyarthritis of Systemic Lupus Erythematosus (SLE)

NCT02429934•University of California, Los Angeles

Summary

This research trial is for patients who have been diagnosed with systemic lupus erythematosus (SLE) with swollen, tender joints (which is called inflammatory polyarthritis) because of the SLE. The purpose of this clinical research study is to evaluate the safety and effectiveness of treatment with abatacept (Abatacept) 125mg injected subcutaneously (under the skin) weekly for 16 weeks versus placebo injections(a substance with no active ingredients and therefore may have no treatment benefit) in subjects with SLE and inflammatory polyarthritis. The effectiveness will be assessed primarily by the number of swollen, tender joints (called a joint count) at each of study visits. Study Medication Abatacept is approved in the U.S. for treating rheumatoid arthritis by prescription and has not been approved by the U.S. Food and Drug Administration for treating SLE yet. In this study, subjects will receive treatment with either abatacept or placebo once a week for 16 weeks (a total of 16 injections).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Meet at least 4 of the 11 American College of Rheumatology (ACR) 1997 criteria for classification of SLE (see Appendix 1).OR meet the recent classification recommended by SLICC (Appendix 2) 6
•2. ≥3 swollen and tender joints on 2 examinations at least 2 weeks apart and no more than 8 weeks apart.
•3. SLEDAI2K score ≥4 indicating active disease.
•4. Documented positive ANA (≥1:80) and/or anti-dsDNA during course of SLE.
•5. Men and women, at least 18 years of age. Women of childbearing potential must use adequate method(s) of contraception to avoid pregnancy throughout the study and for up to 2 months after last study drug dose. They must have a negative serum or urine pregnancy test prior to the start of study medication.
•6. Background therapies allowed: antimalarials (dose constant for ≥ one month before study entry and during 16 weeks of trial), methotrexate (same criteria as for antimalarials), azathioprine (same criteria), mycophenolate (same criteria), leflunomide (same criteria).
•During the screening period and for up to 6 weeks after randomization, a daily prednisone (or equivalent) regimen of up to 20 mg daily may be initiated to treat the moderate to severe disease activity present at screening. The initial steroid regimen is not required if investigators or patients believe that the risks would outweigh the potential benefits. Patients who do not take any glucocorticoids during the study will be included in the treatment groups and analysis.
•\*Steroids should be tapered to a target dose of no more than 10 mg/day of prednisone (or equivalent) by the end of Week 8 (Day 56). The steroid regimen should be tapered as quickly as safely possible. Prednisone dose requirements higher than 10 mg daily at the 8 week visit will cause the patient to be ruled a non-responder for the abatacept treatment arm.

Exclusion Criteria

•1. Subjects with active infection requiring oral or IV antibiotics within one month of first dose of study medication.
•2. Subjects with BILAG A in any system outside the musculoskeletal system.
•3. Subjects with positive quantiferon Gold test in the absence of treatment for tuberculosis.
•4. Subjects with positive tests for active infection with hepatitis B or C during the past 6 months. Any confirmed positive test for HIV at any time prior to entry into this study.
•5. Subjects with active glomerulonephritis (\>3 g protein/24h and/or active urine sediment).
•6. Subjects with active CNS disease.
•7. Subjects with any other serious disease that would require immunosuppressive or parenteral anti-microbial therapy outside the study protocol.
•8. Inability to self-administer subcutaneous injections, to comply with instructions, or to keep appointments for study visits.
•9. Treatment with rituximab within the past 6 months (B cells must be detectable in peripheral blood at onset of treatment with study biologic), belimumab within the past 5 months, cyclophosphamide within the past 3 months.
•10. Treatment with any other immunomodulatory biologic or cyclophosphamide during treatment with abatacept is not allowed.
+5 more criteria

Locations (2)

UCLA David Geffen School of Medicine, Division of Rheumatology

Los Angeles, California, United States

University of California, San Diego

San Diego, California, United States

Key Dates

Start Date

October 1, 2015

Primary Completion Date

September 1, 2019

Completion Date

September 1, 2019

Last Updated

May 13, 2021

Enrollment

ACTUAL participants

Conditions

Systemic Lupus Erythematosus Arthritis

Interventions

abatacept also known as Orencia also known as CTLA4-Ig

BIOLOGICAL

Placebo

DRUG